Amanote Research
Register
Sign In
Pcv19 a Bayesian Multiple Treatment Comparison of Pulmonary Arterial Hypertension Drug Classes Based on the Risk of Mortality Reported in Clinical Trials
Value in Health
- United Kingdom
doi 10.1016/j.jval.2011.02.207
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2011
Authors
A. Mutebi
D. Malone
Publisher
Elsevier BV
Related search
Phase 2 and 3 Clinical Trials in Pulmonary Arterial Hypertension
Advances in Pulmonary Hypertension
Mortality-Related Risk Factors in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The Importance of Response to Treatment
Open Journal of Respiratory Diseases
A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
A Focus on Riociguat in the Treatment of Pulmonary Arterial Hypertension
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
Motivations of Patients With Pulmonary Arterial Hypertension to Participate in Randomized Clinical Trials
Clinical Trials
Medicine
Pharmacology
Adenosine Receptors as Drug Targets for Treatment of Pulmonary Arterial Hypertension
Frontiers in Pharmacology
Pharmacology
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
Advances in Pulmonary Hypertension
Treatment of Pulmonary Arterial Hypertension in Pregnancy
American Journal of Health-System Pharmacy
Medicine
Health Policy
Pharmacology
Pharmacy
Clinical End-Points and Surrogate Markers of Pulmonary Arterial Hypertension in the Light of Evidence-Based Treatment
Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
